274
Views
1
CrossRef citations to date
0
Altmetric
ORIGINAL RESEARCH

Dupilumab Treatment Efficacy and Impact on Clinical Scores, Serum Biomarkers, and Itch in Adult Patients with Atopic Dermatitis: A Retrospective Analysis

, ORCID Icon, , , &
Pages 1233-1240 | Received 01 Sep 2023, Accepted 25 Oct 2023, Published online: 08 Nov 2023

References

  • Nutten S. Atopic dermatitis: global epidemiology and risk factors. Ann Nutr Metab. 2015;66(Suppl. 1):8–16. doi:10.1159/000370220
  • Eichenfield LF, Tom WL, Chamlin SL, et al. Guidelines of care for the management of atopic dermatitis: part 1: diagnosis and assessment of atopic dermatitis. J Am Acad Dermatol. 2014;70(2):338. doi:10.1016/j.jaad.2013.10.010
  • Chopra R, Silverberg JI. Assessing the severity of atopic dermatitis in clinical trials and practice. Clin Dermatol. 2018;36(5):606–615. doi:10.1016/j.clindermatol.2018.05.012
  • Kato A, Kamata M, Ito M, et al. Higher baseline serum lactate dehydrogenase level is associated with poor effectiveness of dupilumab in the long term in patients with atopic dermatitis. J Dermatol. 2020;47(9):1013–1019. doi:10.1111/1346-8138.15464
  • Wu KG, Li TH, Chen CJ, Cheng HI, Wang TY. Correlations of serum interleukin-16, total ige, eosinophil cationic protein and total eosinophil counts with disease activity in children with atopic dermatitis. Int J Immunopathol Pharmacol. 2011;24(1):15–23. doi:10.1177/039463201102400103
  • Dhar S, Malakar R, Chattopadhyay S, Dhar S, Banerjee R, Ghosh A. Correlation of the severity of atopic dermatitis with absolute eosinophil counts in peripheral blood and serum ige levels. Indian J Dermatol Venereol Leprol. 2005;71(4):246–249. doi:10.4103/0378-6323.16615
  • Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115–S123.
  • Gelmetti C, Girolomoni G, Patrizi A. Critical review of guidelines and practical recommendations for the management of patients with atopic dermatitis. Dermatite Atopica 2016–2017 SIDeMaST; 2016. Available from: www.aidro.org. Accessed April 12, 2023.
  • Wollenberg A, Thomsen SF, Lacour JP, Jaumont X, Lazarewicz S. Targeting immunoglobulin E in atopic dermatitis: a review of the existing evidence. World Allergy Organ J. 2021;14(3):100519. doi:10.1016/j.waojou.2021.100519
  • Mogensen TH. Primary immunodeficiencies with elevated ige. Int Rev Immunol. 2016;35(1):39–56. doi:10.3109/08830185.2015.1027820
  • Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled Phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184(3):437–449. doi:10.1111/bjd.19574
  • Deleuran M, Thaçi D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a Phase 3 open-label extension study. J Am Acad Dermatol. 2020;82(2):377–388. doi:10.1016/j.jaad.2019.07.074
  • Silvestre Salvador JF, Romero-Pérez D, Encabo-Durán B. Atopic dermatitis in adults: a diagnostic challenge. J Investig Allergol Clin Immunol. 2017;27(2):78–88. doi:10.18176/jiaci.0138
  • Wechsler ME, Klion AD, Paggiaro P, et al. Effect of dupilumab on blood eosinophil counts in patients with asthma, chronic rhinosinusitis with nasal polyps, atopic dermatitis, or eosinophilic esophagitis. J Allergy Clin Immunol Pract. 2022;10(10):2695–2709. doi:10.1016/j.jaip.2022.05.019
  • Italian Medical Agency (AIFA, Agenzia Italiana Farmaco). Dupilumab: assessment of innovativeness. WWW document; 2020. Available from: https://www.aifa.gov.it/documents/20142/1308577/97_Dupixent_14869_scheda_innovativita_GRADE.pdf. Accessed April 12, 2023.
  • de Bruin-Weller M, Thaçi D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178(5):1083–1101. doi:10.1111/bjd.16156
  • Forkasiewicz A, Dorociak M, Stach K, Szelachowski P, Tabola R, Augoff K. The usefulness of lactate dehydrogenase measurements in current oncological practice. Cell Mol Biol Lett. 2020;25(1). doi:10.1186/s11658-020-00228-7
  • Thijs J, Krastev T, Weidinger S, et al. Biomarkers for atopic dermatitis: a systematic review and meta-analysis. Curr Opin Allergy Clin Immunol. 2015;15(5):453–460. doi:10.1097/ACI.0000000000000198
  • Kogawa K, Minakawa S, Matsuzaki Y, et al. Correlation between lactate dehydrogenase and other laboratory data in patients with atopic dermatitis. J Cutan Immunol Allergy. 2022;5(4):133–135. doi:10.1002/cia2.12225
  • Holm JG, Agner T, Clausen ML, Thomsen SF. Determinants of disease severity among patients with atopic dermatitis: association with components of the atopic march. Arch Dermatol Res. 2019;311(3):173–182. doi:10.1007/s00403-019-01895-z
  • Stone SP. Atopic dermatitis and ige. relationship between changes in ige levels and severity of disease. Arch Dermatol. 1976;112(9):1254–1255. doi:10.1001/archderm.1976.01630330024005
  • Laske N, Niggemann B. Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol. 2004;15(1):86–88. doi:10.1046/j.0905-6157.2003.00106.x
  • Joishy M, Alfaham M, Tuthill D. Does the severity of atopic dermatitis correlate with serum IgE levels? Pediatr Allergy Immunol. 2005;16(3):283. doi:10.1111/j.1399-3038.2005.00212.x
  • Renert-Yuval Y, Del Duca E, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148(1):148–163. doi:10.1016/j.jaci.2021.01.001
  • Askin O, Yucesoy SN, Serdaroglu S. The evaluation of dupilumab treatment response in atopic dermatitis patients. North Clin Istanbul. 2020;8:2.
  • Mizuno M, Horiguchi G, Teramukai S, et al. Association study of transition of laboratory marker levels and transition of disease activity of atopic dermatitis patients treated with dupilumab. Australas J Dermatol. 2021;62(4):e504–e509. doi:10.1111/ajd.13719
  • Renert-Yuval Y, Thyssen JP, Bissonnette R, et al. Biomarkers in atopic dermatitis-A review on behalf of the international eczema council. J Allergy Clin Immunol. 2021;147(4):1174–1190.e1. doi:10.1016/j.jaci.2021.01.013
  • Hagino T, Saeki H, Fujimoto E, Kanda N. The eosinophil-to-lymphocyte ratio acts as an indicator for improvement of clinical signs and itch by upadacitinib treatment in atopic dermatitis. J Clin Med. 2023;12(6):2201. doi:10.3390/jcm12062201
  • Hagino T, Saeki H, Kanda N. The efficacy and safety of upadacitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2022;49(11):1158–1167. doi:10.1111/1346-8138.16549
  • Hagino T, Saeki H, Fujimoto E, Kanda N. Efficacy and safety of baricitinib treatment for moderate to severe atopic dermatitis in real-world practice in Japan. J Dermatol. 2023;50(7):869–879. doi:10.1111/1346-8138.16763
  • Stalder JF, Taïeb A, Atherton DJ, et al. Severity scoring of atopic dermatitis: the scorad index. consensus report of the European task force on atopic dermatitis. Dermatology. 1993;186(1):23–31.
  • Ständer S, Steinhoff M. Pathophysiology of pruritus in atopic dermatitis: an overview. Exp Dermatol. 2002;11(1):12–24. doi:10.1034/j.1600-0625.2002.110102.x
  • Reich A, Riepe C, Anastasiadou Z, et al. Itch assessment with visual analogue scale and numerical rating scale: determination of minimal clinically important difference in chronic itch. Acta Derm Venereol. 2016;96(7):978–980. doi:10.2340/00015555-2433
  • Legat FJ. Itch in atopic dermatitis - what is new? Front Med . 2021;8:644760. doi:10.3389/fmed.2021.644760